Emergent presents prostate cancer therapeutic preclinical data
Emergent presented on ES414, a molecular protein technology therapeutic developed using the company's ADAPTIR technology platform, during the 5th Annual Protein and Antibody Engineering Summit. The candidate is being developed as a therapeutic for metastatic castration-resistant prostate cancer.
The preclinical studies demonstrated that ES414 is pharmacologically active and well tolerated. Preclinical in vitro and in vivo studies found that ES414 redirects T-cell cytotoxicity toward prostate cancer cells expressing prostate specific membrane antigen, triggering the destruction of tumor cells.
"The encouraging ES414 preclinical data support our efforts to both engage the scientific community and further generate partnering interest in our biosciences programs," Barry Labinger, the executive vice president of Emergent, said. "We believe certain features of ES414 including activity at very low doses, minimal cytokine release on binding to target and T cells, and a long half-life, make it a promising molecule for continued development. Additionally, the company has a defined, scalable process for Phase I clinical manufacturing of ES414 and is proceeding toward filing an investigational new drug application."
There are approximately 230,000 new cases of prostate cancer annually in the U.S., making it the most common cancer in men. There are few options available to treat metastatic castration-resistant prostate cancer.